Clinical Trial

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-03.
Trial Details
NCT Number NCT07063212
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Gilead Sciences
Conditions Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma +4 more
Enrollment 40 participants
Start Date 2025-07-02
Primary Completion 2028-01-02 (estimated)
Study Completion 2028-01-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-19